| Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4 S Qin, L Xu, M Yi, S Yu, K Wu, S Luo Molecular cancer 18, 1-14, 2019 | 1020 | 2019 |
| Combination strategies with PD-1/PD-L1 blockade: current advances and future directions M Yi, X Zheng, M Niu, S Zhu, H Ge, K Wu Molecular cancer 21 (1), 28, 2022 | 772 | 2022 |
| Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors M Yi, D Jiao, H Xu, Q Liu, W Zhao, X Han, K Wu Molecular cancer 17, 1-14, 2018 | 726 | 2018 |
| Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment M Yi, D Jiao, S Qin, Q Chu, K Wu, A Li Molecular cancer 18, 1-12, 2019 | 504 | 2019 |
| Regulation of PD-L1 expression in the tumor microenvironment M Yi, M Niu, L Xu, S Luo, K Wu Journal of hematology & oncology 14, 1-13, 2021 | 447 | 2021 |
| Organoid technology and applications in cancer research H Xu, X Lyu, M Yi, W Zhao, Y Song, K Wu Journal of hematology & oncology 11, 1-15, 2018 | 326 | 2018 |
| Recent advances on anti-angiogenesis receptor tyrosine kinase inhibitors in cancer therapy S Qin, A Li, M Yi, S Yu, M Zhang, K Wu Journal of hematology & oncology 12, 1-11, 2019 | 311 | 2019 |
| Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy A Li, M Yi, S Qin, Y Song, Q Chu, K Wu Journal of hematology & oncology 12, 1-12, 2019 | 290 | 2019 |
| Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity S Yu, M Yi, S Qin, K Wu Molecular cancer 18, 1-13, 2019 | 271 | 2019 |
| The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of … M Yi, A Li, L Zhou, Q Chu, Y Song, K Wu Journal of hematology & oncology 13, 1-16, 2020 | 227 | 2020 |
| Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy Y Wu, M Yi, M Niu, Q Mei, K Wu Molecular cancer 21 (1), 184, 2022 | 213 | 2022 |
| The role of cancer-derived microRNAs in cancer immune escape M Yi, L Xu, Y Jiao, S Luo, A Li, K Wu Journal of hematology & oncology 13, 1-14, 2020 | 188 | 2020 |
| Gut microbiome modulates efficacy of immune checkpoint inhibitors M Yi, S Yu, S Qin, Q Liu, H Xu, W Zhao, Q Chu, K Wu Journal of hematology & oncology 11, 1-10, 2018 | 177 | 2018 |
| The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-β and PD-L1 M Yi, J Zhang, A Li, M Niu, Y Yan, Y Jiao, S Luo, P Zhou, K Wu Journal of hematology & oncology 14, 1-22, 2021 | 149 | 2021 |
| The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction S Li, M Yi, B Dong, X Tan, S Luo, K Wu International journal of cancer 148 (11), 2640-2651, 2021 | 136 | 2021 |
| Blocking TGF-β signaling to enhance the efficacy of immune checkpoint inhibitor X Bai, M Yi, Y Jiao, Q Chu, K Wu OncoTargets and therapy, 9527-9538, 2019 | 124 | 2019 |
| Advances and perspectives of PARP inhibitors M Yi, B Dong, S Qin, Q Chu, K Wu, S Luo Experimental hematology & oncology 8, 1-12, 2019 | 121 | 2019 |
| The role of neoantigen in immune checkpoint blockade therapy M Yi, S Qin, W Zhao, S Yu, Q Chu, K Wu Experimental hematology & oncology 7, 1-11, 2018 | 118 | 2018 |
| Prospects for combining immune checkpoint blockade with PARP inhibition A Li, M Yi, S Qin, Q Chu, S Luo, K Wu Journal of hematology & oncology 12, 1-12, 2019 | 114 | 2019 |
| Immune signature-based risk stratification and prediction of immune checkpoint inhibitor’s efficacy for lung adenocarcinoma M Yi, A Li, L Zhou, Q Chu, S Luo, K Wu Cancer Immunology, Immunotherapy 70, 1705-1719, 2021 | 113 | 2021 |
